Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk Chair Helge Lund and six other board members to step down
08:04am, Tuesday, 21'st Oct 2025
Wegovy-maker Novo Nordisk said on Tuesday its Chair Helge Lund and six other board members will step down at an upcoming extraordinary general meeting on November 14.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Oct 2025)
07:15am, Tuesday, 21'st Oct 2025
Ozempic has become a phenomenon, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Insight: Novo Nordisk fights to keep Medicaid paying for weight-loss drugs
06:03am, Tuesday, 21'st Oct 2025
Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs, according to state doc
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall
05:05am, Tuesday, 21'st Oct 2025
"Buying the dip" can be a double-edged sword for investors. Sometimes they can seize the opportunity by purchasing an oversold stock, but other times, that stock is trending lower for a good reason (a
My Top 3 Pharma Stocks
11:38am, Monday, 20'th Oct 2025
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
09:07am, Monday, 20'th Oct 2025
The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means, am
President Trump targets $150 MFN price for GLP-1s
07:32pm, Friday, 17'th Oct 2025
Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1
FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk
06:01pm, Friday, 17'th Oct 2025
The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
05:25pm, Friday, 17'th Oct 2025
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of th
Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting
04:43pm, Friday, 17'th Oct 2025
Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglo
Trump says Ozempic prices will be 'much lower' for Americans
03:51pm, Friday, 17'th Oct 2025
President Donald Trump said there will be lower prices for Ozempic after negotiations with Novo Nordisk as part of his broader initiative to reduce prescription drug costs.
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
12:46pm, Friday, 17'th Oct 2025
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
12:15pm, Friday, 17'th Oct 2025
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Li
Is Trump Going to Kill the GLP-1 Cash Cow?
11:05am, Friday, 17'th Oct 2025
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but Pres
Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts
10:51am, Friday, 17'th Oct 2025
Novo Nordisk has appointed U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, according to a statement he posted on LinkedIn, as the obesity drugmaker faces growing pressur
